Mga Batayang Estadistika
| LEI | 875500HKJS7QQG6EWH62 |
| CIK | 1855129 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GH Research PLC
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pr |
|
| August 7, 2025 |
Exhibit 99.3 GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates August 7, 2025 • Global pivotal program initiation on track for 2026 • Engagement with FDA on GH001 IND complete response ongoing • The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapy • Treatment was well |
|
| August 7, 2025 |
Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Note $’000 $’000 $’000 $’000 Operating expenses Research and development 3 (8,958 ) (9,755 ) (16,810 ) (18,413 ) General and administration 3 (5,746 ) (3,464 ) (10,626 ) (6,334 ) Loss from operations (14,704 ) (13,219 ) (27, |
|
| August 7, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pr |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pr |
|
| July 29, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-285310) and on Form S-8 (Nos. 333-270422 and 333-285311) of GH Research PLC of our report dated February 27, 2025 relating to the financial statements, which appears in this Form 20-F/A. /s/ PricewaterhouseCoopers Dublin, Ire |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| July 29, 2025 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Velichka Valcheva, certify that: 1. I have reviewed this Annual Report on Form 20-F/A of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to stat |
|
| July 29, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F/A for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act |
|
| July 29, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F/A for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act |
|
| July 29, 2025 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Julie Ryan, certify that: 1. I have reviewed this Annual Report on Form 20-F/A of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of prin |
|
| July 23, 2025 |
GH Research Announces Global Pivotal Program Plans and Further Development Updates Exhibit 99.1 GH Research Announces Global Pivotal Program Plans and Further Development Updates • Engagement with FDA on GH001 IND complete response ongoing • The fully completed Open Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapy • Treatment was well tolerated and no treatment related serious adverse events were reported. T |
|
| July 23, 2025 |
Exhibit 99.2 GH Research R&D Update July 2025 This presentation has been prepared by GH Research PLC (“GH Research”). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or adviser of GH Research. This presentation does not purport to be all-inclusive or to contain all of |
|
| June 20, 2025 |
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule Exhibit 99.1 GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule Dublin, Ireland, June 20, 2025 – GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, it submitted its complete response to the previously announced clinic |
|
| June 20, 2025 |
6-K 1 ef200508476k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY |
|
| June 18, 2025 |
Exhibit 99.3 You invested in GH RESEARCH PLC and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on July 31, 2025. Get informed before you vote View the Notice of Annual General Meeting, Irish Statutory Financial Statements, Form 20-F onl |
|
| June 18, 2025 |
Exhibit 99.6 1.1 - Florian Schönharting 1.4 - Duncan Moore, PhD 1.2 - Michael Forer, LL.B. 1.3 - Dermot Hanley 1 U P X For Against Abstain For Against Abstain For Against Abstain The Sample Company 045XXC 3. To renew the Board’s existing authority under Irish law to allot and issue ordinary shares. 1. Election of Directors: For Against Abstain For Against Abstain Please sign exactly as your name(s |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of prin |
|
| June 18, 2025 |
Exhibit 99.1 Notice of Annual General Meeting to be held on 31 July 2025 GH Research plc (the Company or GH Research) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you are taking advice in Ireland, is authorised or exempted under the European Communities (Mar |
|
| June 18, 2025 |
Number of Ordinary Shares Beneficially Owned Exhibit 99.2 Directors’ Report and Financial Statements GH Research PLC Directors’ Report and Financial Statements Directors’ Report 2 Statement of Directors’ Responsibilities 93 Independent auditors’ report to the members of GH Research PLC 94 Consolidated Statement of Comprehensive Loss 100 Consolidated Statement of Financial Position 101 Consolidated Statement of Changes in Equity 102 Consolida |
|
| June 18, 2025 |
Exhibit 99.5 1.1 - Florian Schönharting 1.4 - Duncan Moore, PhD 1.2 - Michael Forer, LL.B. 1.3 - Dermot Hanley 4 3 B M For Against Abstain For Against Abstain For Against Abstain The Sample Company Proposals — The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposals 2, 3 and 4. A 045XWC 2. To ratify the appointment of PricewaterhouseCoopers Ireland as independent audi |
|
| June 18, 2025 |
Exhibit 99.4 Step 1: Step 2: Step 3: Step 4: Step 5: Go to www.envisionreports.com/ghrs. Click on Cast Your Vote or Request Materials. Follow the instructions on the screen to log in. Make your selections as instructed on each screen for your delivery preferences. Vote your shares. www.envisionreports.com/ghrs Easy Online Access — View your proxy materials and vote. Online Go to www.envisionreport |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of prin |
|
| May 27, 2025 |
Exhibit 99.1 Safety and Efficacy of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomized Controlled Trial Michael E. Thase, MD Department of Psychiatry, University of Pennsylvania, and Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA Coauthors: Bernhard T. Baune, Narcís Cardoner, Rosa Maria Dueñas Herrero, Luboš Janů, John R. Kell |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| May 21, 2025 |
Exhibit 99.3 Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients With Postpartum Depression Claus Bo Svendsen,1* Emilio Arbe,2 Sem E. Cohen,3 Kristina M. Deligiannidis,4 William Gann,5 Sarah Keady,1 Rachael MacIsaac,1 Stuart Ratcliffe,2 David R. Rubinow,6 Dan Tully,5 Velichka Valcheva,1 Jasper B. Zantvoord,3 Martin Johnson2 1GH Research, Dublin, Ireland; 2St. Pancras Cl |
|
| May 21, 2025 |
Exhibit 99.2 Safety and Tolerability of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomized, Controlled Trial Wiesław J. Cubała,1* Bernhard T. Baune,2 Narcís Cardoner,3 Rosa Maria Dueñas Herrero,4 Luboš Janů,5 John R. Kelly,6 Shane J. McInerney,7 Alexander Nawka,8 Tomáš Páleníček,9 Andreas Reif,10 Victor Perez Sola,11-14 Madhukar H. Trivedi,15 Velichka Valche |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| May 21, 2025 |
Exhibit 99.1 Safety and Efficacy of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomized Controlled Trial Michael E. Thase,1,2* Bernhard T. Baune,3 Narcís Cardoner,4 Rosa Maria Dueñas Herrero,5 Luboš Janů,6 John R. Kelly,7 Shane J. McInerney,8 Alexander Nawka,9 Tomáš Páleníček,10 Andreas Reif,11 Víctor Pérez Sola,12-15 Madhukar H. Trivedi,16 Velichka Valcheva, |
|
| May 15, 2025 |
Exhibit 99.1 GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting Dublin, Ireland, May 15, 2025 – GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| May 8, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| May 8, 2025 |
Exhibit 99.3 GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates May 8, 2025 • Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reduction • Full response to the IND hold on track for submission in mid-2025 • Cash, cash equivalents, other financial assets and marketable securities of $315.3 million as of Mar |
|
| May 8, 2025 |
Exhibit 99.4 GH Research PLC (NASDAQ: GHRS) May 2025 Corporate Presentation 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or advis |
|
| May 8, 2025 |
Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended March 31, 2025 2024 Note $’000 $’000 Operating expenses Research and development 3 (7,852 ) (8,658 ) General and administration 3 (4,880 ) (2,870 ) Loss from operations (12,732 ) (11,528 ) Finance income 4 2,759 2,670 Finance expense 4 (178 ) (179 ) Movement of expected credit l |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| March 5, 2025 |
March 5, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 27, 2025 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our share capital is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to Irish law, including without limitation the Irish Companies Act 2014 (as amended) (referred to herein as the Iri |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| February 27, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-270418) and on Form S-8 (No. 333-270422) of GH Research PLC of our report dated February 27, 2025 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers Dublin, Ireland February 27, 2 |
|
| February 27, 2025 |
Exhibit 99.1 GH Research Reports Full Year 2024 Financial Results and Provides Business Updates • Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 • Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK • Full response to t |
|
| February 27, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
|
| February 27, 2025 |
Exhibit 4.1 Rules of the GH Research PLC Share Option Plan Board Approval on June 20, 2021 (and amended by the Committee on November 24, 2024) Contents 1 Establishment and Purpose 1 2 Definitions 1 3 Administration 3 4 Eligibility for participation 3 5 Limitation as to Participation 3 6 Grant of Options 3 7 Limitations on Grant of Options 4 8 Specific Terms of Options 5 9 Non-transfer of Option 5 |
|
| February 27, 2025 |
Exhibit 11.1 Statement of Policy Concerning Trading in Group Securities GH Research PLC Statement of Policy Concerning Trading in Group Securities Adopted by resolution of the Board on 26 February 2025 Table of Contents 1. Rationale and Objective 2 2. Scope 2 3. The Use of Inside Information in Connection with Trading in Securities 2 4. Other Limitations on Securities Transactions 9 5. Contacts 11 |
|
| February 27, 2025 |
Calculation of Filing Fee Tables Form F-3 Exhibit 107.1 Calculation of Filing Fee Tables Form F-3 (Form Type) GH Research PLC (Exact Name of registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) GH Research PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (6) Fees to be Paid Equity Ordinary Shares, nominal value $0. |
|
| February 27, 2025 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Velichka Valcheva, certify that: 1. I have reviewed this Annual Report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| February 27, 2025 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Julie Ryan, certify that: 1. I have reviewed this Annual Report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 27, 2025. |
|
| February 27, 2025 |
POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION GH RESEARCH PLC CLAWBACK POLICY Exhibit 97.1 POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION GH RESEARCH PLC CLAWBACK POLICY Introduction The Board of Directors (the "Board") of GH Research PLC (the "Company") believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability, that reinforces the Company's pay-for-performance com |
|
| February 27, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
|
| February 6, 2025 |
GH Research PLC 10,000,000 Ordinary Shares (Nominal Value $0.025 Each) UNDERWRITING AGREEMENT Exhibit 1.1 GH Research PLC 10,000,000 Ordinary Shares (Nominal Value $0.025 Each) UNDERWRITING AGREEMENT February 4, 2025 Cantor Fitzgerald & Co. Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters c/o Cantor Fitzgerald & Co. 110 East 59th Street New York, New York 10022 c/o Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, New York |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| February 5, 2025 |
Exhibit 107.1 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price for the securities to which such prospectus relates that are being offered by GH Research PLC is $172,500,000. |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| February 5, 2025 |
GH Research Announces Pricing of $150 Million Public Offering Exhibit 99.1 GH Research Announces Pricing of $150 Million Public Offering Dublin, Ireland, February 4, 2025 – GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States o |
|
| February 5, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No.333-270418 PROSPECTUS SUPPLEMENT (to Prospectus dated March 17, 2023) 10,000,000 Ordinary Shares GH Research PLC We are offering 10,000,000 ordinary shares, nominal value $0.025 per share. The public offering price is $15.00 per share. Our ordinary shares are listed on the Nasdaq Global Market, or Nasdaq, under the symbol “GHRS”. |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| February 3, 2025 |
SUBJECT TO COMPLETION, DATED FEBRUARY 3, 2025 TABLE OF CONTENTS The information contained in this prospectus supplement is not complete and may be changed. |
|
| February 3, 2025 |
Exhibit 99.1 GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction • Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001) • The majority of the patients treated with GH001 achieved remission with a 57. |
|
| February 3, 2025 |
Exhibit 99.1 Risk Factors Our business is subject to a number of risks. You should carefully consider all of the information set forth in documents we file with or furnish to the U.S. Securities and Exchange Commission, or SEC, including the following risk factors, before deciding to invest in or to maintain an investment in our securities. Our business, as well as our reputation, financial condit |
|
| February 3, 2025 |
Exhibit 99.2 A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial with an Open-Label Extension to Determine the Safety and Efficacy of GH001 in Patients with Treatment-Resistant DepressionGH001-TRD-201 Clinicaltrials.gov ID: NCT05800860 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| February 3, 2025 |
GH Research Announces Proposed Public Offering Exhibit 99.1 GH Research Announces Proposed Public Offering Dublin, Ireland, February 3, 2025 – GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary share |
|
| February 3, 2025 |
Exhibit 99.2 Information on the Company A. History and Development of the Company GH Research PLC was incorporated as a public limited company under the laws of Ireland on March 29, 2021 to become a holding company for GH Research Ireland Limited. GH Research Ireland Limited was originally incorporated under the laws of Ireland on October 16, 2018 as GH Research Limited. GH Research Limited was re |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of p |
|
| January 31, 2025 |
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD Exhibit 99.1 GH Research to Provide Update on Phase 2b Trial with GH001 in TRD Dublin, Ireland, January 31, 2025 – GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide a |
|
| January 10, 2025 |
Exhibit 99.2 GH Research PLC (NASDAQ: GHRS) January 2025 Corporate Presentation 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or a |
|
| January 10, 2025 |
Exhibit 99.1 GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents • Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8 • Primary en |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of p |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| November 14, 2024 |
GHRS / GH Research PLC / Lynx1 Capital Management LP - GH RESEARCH PLC Passive Investment SC 13G/A 1 p24-3209sc13ga.htm GH RESEARCH PLC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GH Research PLC (Name of Issuer) Ordinary shares, nominal value $0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| November 14, 2024 |
Three months ended September 30, Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive income Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Note $’000 $’000 $’000 $’000 Operating expenses Research and development 3 (8,397 ) (7,088 ) (26,810 ) (21,570 ) General and administration 3 (4,224 ) (2,631 ) (10,558 ) (8,493 ) Loss from operations (12,621 ) ( |
|
| November 14, 2024 |
GHRS / GH Research PLC / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d13sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* GH Research PLC (Name of Issuer) Ordinary Shares, Nominal value of $ 0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat |
|
| November 14, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 3 ef20035537ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated int |
|
| November 14, 2024 |
Exhibit 99.3 GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates November 14, 2024 • Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024 • Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK • Cash, cash equivalents, |
|
| November 14, 2024 |
EX-99.1 2 tm2427451d13ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 14, 2024 |
Exhibit 99.4 GH Research PLC (NASDAQ: GHRS) November 2024 Corporate Presentation 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 20, 2024 |
Exhibit 99.1 19/09/2024 1 Review of Ongoing Phase 2b Treatment-Resistant Depression Clinical Trial (GH001-TRD-201) Wiesław J. Cubała Medical University of Gdańsk Author Disclosure 19/09/2024 2 Conflict of interest statement regarding my presentation in the ‘Industry session financially supported by GH Research during the 37th ECNP congress.’ Review of Ongoing Phase 2b TRD Clinical Trial (GH001-TRD |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 9, 2024 |
6-K 1 ef200356596k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D |
|
| September 3, 2024 |
Exhibit 99.3 GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates • Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025 • Phase 1 clinical trial to evaluate proprietary aerosol delivery device in h |
|
| September 3, 2024 |
Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive income Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Note $’000 $’000 $’000 $’000 Operating expenses Research and development 3 (9,755 ) (7,176 ) (18,413 ) (14,482 ) General and administration 3 (3,464 ) (2,749 ) (6,334 ) (5,862 ) Loss from operations (13,219 ) (9,925 ) (24, |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 3, 2024 |
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer Exhibit 99.1 GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer DUBLIN, Ireland, September 03, 2024 - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka “Villy“ Valcheva, MD, MSc. to Chief Executive Offic |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 3, 2024 |
Exhibit 99.2 GH Research PLC (NASDAQ: GHRS) September 2024 Corporate Presentation 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 3, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of prin |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of prin |
|
| May 15, 2024 |
Number of Ordinary Shares Beneficially Owned Exhibit 99.2 Directors’ Report and Financial Statements GH Research PLC Directors’ Report and Financial Statements Directors’ Report 2 Statement of Directors’ Responsibilities 93 Independent auditors’ report to the members of GH Research PLC 94 Consolidated Statement of Comprehensive Income 100 Consolidated Statement of Financial Position 101 Consolidated Statement of Changes in Equity 102 Consoli |
|
| May 15, 2024 |
Exhibit 99.4 Step 1: Step 2: Step 3: Step 4: Step 5: Go to www.envisionreports.com/ghrs. Click on Cast Your Vote or Request Materials. Follow the instructions on the screen to log in. Make your selections as instructed on each screen for your delivery preferences. Vote your shares. www.envisionreports.com/ghrs Easy Online Access — View your proxy materials and vote. Online Go to www.envisionreport |
|
| May 15, 2024 |
Exhibit 99.3 You invested in GH RESEARCH PLC and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 27, 2024. Get informed before you vote View the Irish Statutory Financial Statements, Notice of Annual General Meeting, Form 20-F onl |
|
| May 15, 2024 |
Exhibit 99.5 1.1 - Florian Schönharting 1.4 - Duncan Moore, PhD 1.2 - Michael Forer, LL.B. 1.3 - Dermot Hanley For Against Abstain For Against Abstain For Against Abstain 1 U P X Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 03ZPGC + + A Proposals — The Board of Directors recommends a vote FOR all the nominees listed an |
|
| May 15, 2024 |
Exhibit 99.1 Notice of Annual General Meeting to be held on 27 June 2024 GH Research plc (the Company or GH Research) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you are taking advice in Ireland, is authorised or exempted under the European Communities (Mar |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| May 15, 2024 |
Exhibit 99.6 1.1 - Florian Schönharting 1.4 - Duncan Moore, PhD 1.2 - Michael Forer, LL.B. 1.3 - Dermot Hanley For Against Abstain For Against Abstain For Against Abstain 1 U P X Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 03ZPLB + + Proposals — The Board of Directors recommends a vote FOR all the nominees listed and |
|
| May 3, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| May 3, 2024 |
Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive income Three Months Ended March 31, 2024 2023 Note $’000 $’000 Operating expenses Research and development 3 (8,658 ) (7,306 ) General and administration 3 (2,870 ) (3,113 ) Loss from operations (11,528 ) (10,419 ) Finance income 4 2,670 1,489 Finance expense 4 (179 ) (171 ) Movement of expected credit |
|
| May 3, 2024 |
Exhibit 99.4 GH Research PLC (NASDAQ: GHRS) May 2024 Corporate Presentation 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or advis |
|
| May 3, 2024 |
Exhibit 99.3 GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates • Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025 • Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pri |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pri |
|
| March 7, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 7, 2024 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our share capital is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to Irish law, including without limitation the Irish Companies Act 2014 (as amended) (referred to herein as the Iri |
|
| March 7, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Theis Terwey, certify that: 1. I have reviewed this Annual Report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| March 7, 2024 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Julie Ryan, certify that: 1. I have reviewed this Annual Report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| March 7, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-270418) and on Form S-8 (No. 333-270422) of GH Research PLC of our report dated March 7, 2024 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers Dublin, Ireland March 7, 2024 |
|
| March 7, 2024 |
POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION GH RESEARCH PLC CLAWBACK POLICY Exhibit 97.1 POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION GH RESEARCH PLC CLAWBACK POLICY Introduction The Board of Directors (the "Board") of GH Research PLC (the "Company") believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability, that reinforces the Company's pay-for-performance com |
|
| March 7, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
|
| February 29, 2024 |
Exhibit 99.2 GH Research PLC (NASDAQ: GHRS) February 2024 Corporate Presentation 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| February 29, 2024 |
Exhibit 99.1 GH Research Reports Full Year 2023 Financial Results and Provides Business Updates • Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 • Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024 • Successfully completed Phase 1, dose-ranging clin |
|
| February 16, 2024 |
GHRS / GH Research PLC / Lynx1 Capital Management LP - GH RESEARCH PLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GH Research PLC (Name of Issuer) Ordinary shares, nominal value $0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) February 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 16, 2024 |
EX-99 2 p24-0865exhibit99.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agree |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga107422ghrs02142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 GH Research PLC (Name of Issuer) Ordinary Shares, nominal value $0 |
|
| February 14, 2024 |
EX-99.1 2 ex991to13ga107422ghrs021424.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2024 with respect to the Ordinary Shares, nominal value $0.025 per share, of GH Research PLC, an Irish company, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf |
|
| February 14, 2024 |
GHRS / GH Research PLC / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d8sc13ga.htm SC 13G/A ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* GH Research PLC (Name of Issuer) Ordinary shares, nominal value $0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement |
|
| February 14, 2024 |
GHRS / GH Research PLC / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* GH Research PLC (Name of Issuer) Ordinary Shares, Nominal value of $ 0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2024 |
EX-99.1 2 tm246065d11ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 14, 2024 |
GHRS / GH Research PLC / RTW INVESTMENTS, LP - GH RESEARCH PLC Passive Investment SC 13G 1 p24-0732sc13g.htm GH RESEARCH PLC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GH Research PLC (Name of Issuer) Ordinary Shares, nominal value $0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appro |
|
| January 18, 2024 |
Exhibit 99.1 GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression DUBLIN, Ireland, Jan 18, 2024 (GLOBE NEWSWIRE) - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and n |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of p |
|
| January 5, 2024 |
Exhibit 99.1 GH Research PLC (NASDAQ: GHRS) January 2024 Corporate Presentation 1 This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or a |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of p |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| November 9, 2023 |
Exhibit 99.4 1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research November 2023 2023© GH Research PLC Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or re |
|
| November 9, 2023 |
Three Months Ended September 30, Exhibit 99.1 Unaudited condensed consolidated interim statement of comprehensive income Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Note $’000 $’000 $’000 $’000 Operating expenses Research and development 3 (7,088 ) (4,620 ) (21,570 ) (13,574 ) General and administration 3 (2,631 ) (2,006 ) (8,493 ) (7,808 ) Loss from operations (9,719 ) (6,626 ) (30,063 ) |
|
| November 9, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| November 9, 2023 |
Exhibit 99.3 GH Research Reports Third Quarter Financial Results and Provides Business Updates DUBLIN, Ireland, November 9, 2023 (GLOBE NEWSWIRE) - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided |
|
| October 6, 2023 |
Exhibit 99.1 Concentration (nM) Mebufotenin Psilocin DMT Determination of inhibition constants for three psychedelic drugs for 5-HT1A and 5-HT2A receptors in postmortem human brain V. McDonald\, S. Cheetham\, M. Burnett\, C. K. Olsen\ 1GH Research, Dublin, Ireland 2Sygnature Discovery, Nottingham, United Kingdom Poster number P.0411 0.015 0.020 0.010 0.005 0.000 1x10+4 1x10+6 1x10-2 1x10+2 1 [3H]M |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of p |
|
| September 29, 2023 |
Exhibit 99.1 GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression DUBLIN, Ireland, September 29, 2023 (GLOBE NEWSWIRE) - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of |
|
| August 23, 2023 |
Exhibit 99.1 Unaudited condensed consolidated interim statement of comprehensive income Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Note $’000 $’000 $’000 $’000 Operating expenses Research and development 3 (7,176 ) (4,240 ) (14,482 ) (8,954 ) General and administration 3 (2,749 ) (2,510 ) (5,862 ) (5,802 ) Loss from operations (9,925 ) (6,750 ) (20,344 ) (14,756 ) Fi |
|
| August 23, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pr |
|
| August 23, 2023 |
Exhibit 99.4 1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research August 2023 2023© GH Research PLC Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or repr |
|
| August 23, 2023 |
Exhibit 99.3 GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates DUBLIN, Ireland, August 23, 2023 (GLOBE NEWSWIRE) - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided |
|
| July 19, 2023 |
Exhibit 99.5 |
|
| July 19, 2023 |
Exhibit 99.1 Notice of Annual General Meeting to be held on 31 August 2023 GH Research plc (the Company or GH Research) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you are taking advice in Ireland, is authorised or exempted under the European Communities (M |
|
| July 19, 2023 |
Exhibit 99.3 |
|
| July 19, 2023 |
The accompanying notes form an integral part of the consolidated financial statements. Exhibit 99.2 Directors’ Report and Financial Statements GH Research PLC Directors’ Report and Financial Statements Directors’ Report 2 Statement of Directors’ Responsibilities 92 Independent auditors’ report to the members of GH Research PLC 93 Consolidated Statement of Comprehensive Income 99 Consolidated Statement of Financial Position 100 Consolidated Statement of Changes in Equity 101 Consolid |
|
| July 19, 2023 |
Exhibit 99.4 |
|
| July 19, 2023 |
Exhibit 99.6 |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of prin |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of prin |
|
| June 2, 2023 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Theis Terwey, certify that: 1. I have reviewed this annual report on Form 20-F/A of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| June 2, 2023 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Julie Ryan, certify that: 1. I have reviewed this annual report on Form 20-F/A of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| June 2, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F/A for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act |
|
| June 2, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F/A for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act |
|
| June 2, 2023 |
Yasin Keshvargar +1 212 450 4839 [email protected] Davis Polk & Wardwell llp 450 Lexington Avenue New York, NY 10017 davispolk.com June 2, 2023 Re: GH Research PLC Form 20-F for the Fiscal Year Ended December 31, 2022 Filed March 9, 2023 File No. 001-40530 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washin |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| May 11, 2023 |
1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research May 2023 2023© GH Research PLC EX-99.4 5 brhc20052646ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research May 2023 2023© GH Research PLC Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be cons |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| May 11, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| May 11, 2023 |
Exhibit 99.3 GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided b |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of princ |
|
| May 11, 2023 |
Exhibi 99.1 UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2023 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive income Three months ended March 31, 2023 2022 Note $’000 $’000 Operating expenses Research and development 3 (7,306 ) (4,714 ) General and administration 3 (3,113 ) (3,292 ) Loss from operations (10,4 |
|
| March 30, 2023 |
GHRS / GH Research PLC / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* GH Research PLC (Name of Issuer) Ordinary Shares, Nominal value of $ 0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) March 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pri |
|
| March 14, 2023 |
March 14, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pri |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of pri |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
of the GH Research PLC Share Option Plan Board Approval on June 20, 2021 Exhibit 99 Rules of the GH Research PLC Share Option Plan Board Approval on June 20, 2021 Contents 1 Establishment and Purpose 1 2 Definitions 1 3 Administration 3 4 Eligibility for participation 3 5 Limitation as to Participation 3 6 Grant of Options 3 7 Limitations on Grant of Options 4 8 Specific Terms of Options 5 9 Non-transfer of Option 5 10 Termination of Service 5 11 Clawback 6 12 Procedure on Exercise of Options 7 13 Lapse of Options 8 14 Change in Control of the Company, Reconstruction & Winding Up 8 15 Tax Indemnity 10 16 Adjustments in the Event of Capitalisation and Rights Issues etc. |
|
| March 9, 2023 |
Constitution of GH Research PLC Exhibit 1.1 Companies Act 2014 PUBLIC LIMITED COMPANY CONSTITUTION OF GH RESEARCH PUBLIC LIMITED COMPANY MEMORANDUM OF ASSOCIATION 1 The name of the Company is GH RESEARCH PUBLIC LIMITED COMPANY. 2 The Company is a public limited company registered under Part 17 of the Companies Act 2014 (the Act). 3 The objects for which the Company is established are: (a) To carry on the business of a holding co |
|
| March 9, 2023 |
Exhibit 4.3 GH Research PLC INDENTURE Dated as of [] [], as Trustee TABLE OF CONTENTS Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 Article 2 The Securities Section 2.01. Issuable in Series 5 Section 2.02. Establishment of Terms of Series of Securities 6 Section 2.03. Execution a |
|
| March 9, 2023 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Theis Terwey, certify that: 1. I have reviewed this annual report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| March 9, 2023 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Julie Ryan, certify that: 1. I have reviewed this annual report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| March 9, 2023 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our share capital is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to Irish law, including without limitation the Irish Companies Act 2014 (as amended) (referred to herein as the Iri |
|
| March 9, 2023 |
Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form F-3 (Form Type) GH Research PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GH Research PLC (Exact name of registrant as specified in Its charter) Not Applicable (Translation of Registrant’s name into English) Ireland NOT APPLICABLE (State or oth |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) GH Research PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (6) Fees to be Paid Equity Ordinary Shares, nominal value $0. |
|
| March 9, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F for the year ended December 31, 2021 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
|
| March 9, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC’s annual report on Form 20-F for the year ended December 31, 2021 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal exec |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal exec |
|
| March 2, 2023 |
Exhibit 99.1 GH Research Reports Full Year 2022 Financial Results and Provides Business Updates DUBLIN, Ireland., March 2, 2023 (GLOBE NEWSWIRE) - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave updates on |
|
| March 2, 2023 |
Exhibit 99.2 1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research March 2023 2023© GH Research PLC Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or repre |
|
| February 14, 2023 |
GHRS / GH Research PLC / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d35sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* GH Research PLC (Name of Issuer) Ordinary Shares, Nominal value of $ 0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2023 |
GHRS / GH Research PLC / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment |
|
| February 10, 2023 |
GHRS / GH Research PLC / Schonharting Florian - FORM SC 13G/A Passive Investment SC 13G/A 1 dp188707sc13ga1-florian.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* GH RESEARCH PLC (Name of Issuer) Ordinary shares, nominal value $0.025 per share (Title of Class of Securities) G3855L106 (CUSIP |
|
| February 10, 2023 |
GHRS / GH Research PLC / Terwey Theis H - FORM SC 13G/A Passive Investment SC 13G/A 1 dp188708sc13ga1-terwey.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* GH RESEARCH PLC (Name of Issuer) Ordinary shares, nominal value $0.025 per share (Title of Class of Securities) G3855L106 (CUSIP |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2023. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal ex |
|
| January 9, 2023 |
GH Research Provides Business Updates and Highlights Key Upcoming Milestones EX-99.1 2 dp186741ex9901.htm EXHIBIT 99.1 Exhibit 99.1 GH Research Provides Business Updates and Highlights Key Upcoming Milestones - Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023 - Development of proprietary aerosol delivery device for GH001 progressed, IND submission with this device expected in Q3 2023 - Phase 1 trial |
|
| January 9, 2023 |
Exhibit 99.2 1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research January 2023 2023© GH Research PLC Disclaimer Regarding Forward - Looking Statements This presentation has been prepared by GH Research PLC (“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or r |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal e |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal e |
|
| November 10, 2022 |
Exhibit 99.4 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research 2022? GH Research PLC 10 November 2022 Disclaimer Regarding Forward-Looking Statements 2022? GH Research PLC 10 This presentation has been prepared by GH Research PLC (?GH Research?) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a rec |
|
| November 10, 2022 |
Exhibit 99.3 GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates Dublin, Ireland, November 10, 2022 ? GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its b |
|
| November 10, 2022 |
Three months ended September 30, Exhibit 99.1 Unaudited condensed consolidated interim statement of comprehensive income Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Note $?000 $?000 $?000 $?000 Operating expenses Research and development (4,620 ) (2,556 ) (13,574 ) (5,202 ) General and administration (2,006 ) (2,110 ) (7,808 ) (3,277 ) Loss from operations (6,626 ) (4,666 ) (21,382 ) (8,47 |
|
| November 10, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| October 14, 2022 |
Exhibit 99.3 INTRODUCTION 5 - Methoxy - N,N - dimethyltryptamine ( 5 - MeO - DMT) is a potent, fast - acting, naturally - occurring psychoactive tryptamine 1 . It is predominantly found in the bufotoxin of the Sonoran Desert toad 2 and was first synthesized in 1936 3 . It acts on the 5 - HT 1 A and 5 - HT 2 A receptors , and it has been suggested that the 5 - HT 1 A subtype is functionally dominan |
|
| October 14, 2022 |
Exhibit 99.4 A Phase 1, Dose - Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5 - Methoxy - N, N - Dimethyltryptamine Formulation (GH001) in Healthy Volunteers 1 Clinicaltrials.gov ID NCT04698603 Johannes Reckweg 1 , Natasha Mason 1 , Cees van Leeuwen 1 , Stefan Toennes 2 , Theis Terwey 3 , Johannes G Ramaekers 1 1. Faculty of Psychology and Neuroscience, Maastricht Univers |
|
| October 14, 2022 |
Exhibit 99.2 A Phase 1/2 Trial of GH001, a Vaporized 5 - Methoxy - N,N - Dimethyltryptamine Formulation, in Patients with Treatment - Resistant Depression (TRD) 1 Clinicaltrials.gov ID NCT04698603 Johannes Reckweg 1 , Cees van Leeuwen 1 , C?cile Henquet 2 , Th?r?se van Amelsvoort 2 , Natasha Mason 1 , Riccardo Paci 1 , Theis Terwey 3 , Johannes G Ramaekers 1 1. Faculty of Psychology and Neuroscien |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal ex |
|
| October 14, 2022 |
Exhibit 99.1 INTRODUCTION Current established treatments for depression are slow - acting, often taking several weeks before potential effects appear, and about one third of patient do not reach remission even after 4 treatment steps 1 . 5 - Methoxy - N,N - dimethyltryptamine ( 5 - MeO - DMT) is a potent, fast - acting, naturally - occurring psychoactive tryptamine 2 . It acts on the 5 - HT 1 A an |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal |
|
| September 21, 2022 |
Exhibit 99.2 INTRODUCTION 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a potent, fast-acting, naturally-occurring psychoactive tryptamine1. It is predominantly found in the bufotoxin of the Sonoran Desert toad2 and was first synthesized in 19363. It acts on the 5-HT1A and 5-HT2A receptors, and it has been suggested that the 5-HT1A subtype is functionally dominant4. 5-MeO-DMT has been used in re |
|
| September 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal |
|
| September 21, 2022 |
Exhibit 99.1 A Phase 1/2 Trial of GH001, a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation, inPatients with Treatment-Resistant Depression (TRD) 1 Clinicaltrials.gov ID NCT04698603 GH001-TRD-102 ICPR 2022 Johannes Reckweg1, Cees van Leeuwen1, C?cile Henquet2, Th?r?se van Amelsvoort2, Natasha Mason1, Riccardo Paci1, Theis Terwey3, Johannes G Ramaekers1 Faculty of Psychology and Neuroscience, |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal exe |
|
| August 23, 2022 |
Exhibit 99.4 1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research August 2022 2022? GH Research PLC Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC (?GH Research?) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or repr |
|
| August 23, 2022 |
Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive income Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Note $?000 $?000 $?000 $?000 Operating expenses Research and development (4,240 ) (1,954 ) (8,954 ) (2,646 ) General and administration (2,510 ) (719 ) (5,802 ) (1,167 ) Loss from operations (6,750 ) (2,673 ) (14,756 ) (3, |
|
| August 23, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| August 23, 2022 |
Exhibit 99.3 GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates Dublin, Ireland, August 23, 2022 ? GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its busine |
|
| August 11, 2022 |
Exhibit 99.6 |
|
| August 11, 2022 |
Exhibit 99.3 |
|
| August 11, 2022 |
Exhibit 99.4 |
|
| August 11, 2022 |
Exhibit 99.5 |
|
| August 11, 2022 |
The accompanying notes form an integral part of the consolidated financial statements. TABLE OF CONTENTS Exhibit 99.2 Directors Report and Financial Statements ? GH Research PLC TABLE OF CONTENTS Directors? Report and Financial Statements Directors? Report ? ? 1 ? ? Statement of Directors? Responsibilities ? ? 82 ? ? Independent auditors? report to the members of GH Research PLC ? ? 83 ? ? Consolidated Statement of Comprehensive Income ? ? 89 ? ? Consolidated Statement of Financial |
|
| August 11, 2022 |
Notice of Annual General Meeting to be held on 22 September 2022 Exhibit 99.1 Notice of Annual General Meeting to be held on 22 September 2022 ? GH Research PLC ? (the Company or GH Research) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you are taking advice in Ireland, is authorised or exempted under the European Communi |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal exe |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal execu |
|
| May 31, 2022 |
Exhibit 99.1 A Phase 1/2 Trial of GH001, a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation, inPatients with Treatment-Resistant Depression (TRD) 1 Clinicaltrials.gov ID NCT04698603 GH001-TRD-102 ASCP 2022 Johannes Reckweg1, Cees van Leeuwen1, C?cile Henquet2, Therese van Amelsvoort2, Natasha Mason1, Riccardo Paci1, Theis Terwey3, Johannes G Ramaekers1 Faculty of Psychology and Neuroscience, |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal execut |
|
| May 27, 2022 |
GHRS / GH Research PLC / Venrock Healthcare Capital Partners II, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* GH Research PLC (Name of Issuer) Ordinary shares, nominal value $0.025 per share (Title of Class of Securities) G3855L106 (CUSIP Number) May 17, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| May 18, 2022 |
6-K 1 dp1733826k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Irelan |
|
| May 18, 2022 |
Exhibit 99.4 1 Corporate Presentation GH Research PLC (NASDAQ: GHRS) GH Research May 2022 2022? GH Research PLC Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC (?GH Research?) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or represe |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal executi |
|
| May 18, 2022 |
Exhibit 99.3 GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates Dublin, Ireland, May 18, 2022 ? GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2022 and gave updates on its business. |
|
| May 18, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the not |
|
| May 18, 2022 |
Exhibit 99.1 UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2022 GH RESEARCH PLC Condensed consolidated interim statement of comprehensive income Three months ended March 31, 2022 2021 Note $?000 $?000 Operating expenses Research and development (4,714 ) (692 ) General and administration (3,292 ) (448 ) Loss from operations (8,006 ) (1,140 ) Fore |
|
| March 28, 2022 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC?s annual report on Form 20-F for the year ended December 31, 2021 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
|
| March 28, 2022 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our share capital is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to Irish law, including without limitation the Irish Companies Act 2014 (as amended) (referred to herein as the Iri |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) 28 Baggot Street Lower Dublin 2 D02 NX43 Ireland (Address of principal execu |
|
| March 28, 2022 |
Securities and Exchange Commission Exhibit 16.1 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Lausanne, March 28, 2022 Commissioners: We have read the statements made by GH Research PLC pursuant to Item 16F(a) of Form 20-F (copy attached), which we understand will be filed with the Securities and Exchange Commission on Form 20-F of GH Research PLC, dated March 28, 2022. We agree with the statements conc |
|
| March 28, 2022 |
Exhibit 99.1 GH Research Reports Full Year 2021 Financial Results and Provides Business Updates Dublin, Ireland, March 28, 2022 ? GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and gave updates on its business. Fou |
|
| March 28, 2022 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Theis Terwey, certify that: 1. I have reviewed this annual report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 28, 2022 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Julie Ryan, certify that: 1. I have reviewed this annual report on Form 20-F of GH Research PLC; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| March 28, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with GH Research PLC?s annual report on Form 20-F for the year ended December 31, 2021 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act o |
